Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomization for efficacy and safety Phase 4 clinical trials of conversion of basal insulin/metformin/lobeglitazone or basal insulin/metformin/linagliptin in insufficient glycemic control type 2 diabetic patients with combination therapy with basal insulin/metformin or basal insulin/metformin/sulfonyl urea or basal insulin/metformin/DPP-4 inhibitor

Trial Profile

Randomization for efficacy and safety Phase 4 clinical trials of conversion of basal insulin/metformin/lobeglitazone or basal insulin/metformin/linagliptin in insufficient glycemic control type 2 diabetic patients with combination therapy with basal insulin/metformin or basal insulin/metformin/sulfonyl urea or basal insulin/metformin/DPP-4 inhibitor

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Lobeglitazone (Primary) ; Insulin; Linagliptin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top